The anti-tumor necrosis factor antibody infliximab was the first biologic drug approved for the treatment of IBD in 1998 and its clinical application improved the outcome for a significant subgroup of treated patients.1 Due to the rising incidence of IBD and the increasing use of biologic agents, substantial healthcare costs now represent a growing economic burden.2 Upon expiry of the patent for originator infliximab, different biosimilars have entered the market. Here, TNF is linked to inflammatory bowel disease.